387 related articles for article (PubMed ID: 34625231)
1. Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.
Fabrizio VA; Curran KJ
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101305. PubMed ID: 34625231
[TBL] [Abstract][Full Text] [Related]
2. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
Gupta S; Kohorst M; Alkhateeb HB
Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391
[TBL] [Abstract][Full Text] [Related]
3. Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
Agrawal V; Murphy L; Pourhassan H; Pullarkat V; Aldoss I
Eur J Haematol; 2024 Feb; 112(2):236-247. PubMed ID: 37772976
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
7. [In vitro studies on the transfer of CAR into leukemia cells due to their residue in the autologous CAR-T cell preparation system for acute B-cell acute lymphoblastic leukemia].
Liu MJ; Mu J; Yuan T; Cui R; Meng JX; Jiang YY; Li YM; Deng Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):140-145. PubMed ID: 33858045
[No Abstract] [Full Text] [Related]
8. [Chimeric antigen receptor (CAR) T cells targeting CD19 for acute lymphoblastic leukemia].
Takahashi Y; Nishio N
Rinsho Ketsueki; 2023; 64(9):1184-1191. PubMed ID: 37899199
[TBL] [Abstract][Full Text] [Related]
9. Failure of ALL recognition by CAR T cells: a review of CD 19-negative relapses after anti-CD 19 CAR-T treatment in B-ALL.
Aparicio-Pérez C; Carmona M; Benabdellah K; Herrera C
Front Immunol; 2023; 14():1165870. PubMed ID: 37122700
[TBL] [Abstract][Full Text] [Related]
10. INSPIRED Symposium Part 1: Clinical Variables Associated with Improved Outcomes for Children and Young Adults treated with Chimeric Antigen Receptor T cells for B cell Acute Lymphoblastic Leukemia.
Myers RM; Jacoby E; Pulsipher MA; Pasquini MC; Grupp SA; Shah NN; Laetsch TW; Curran KJ; Schultz LM
Transplant Cell Ther; 2023 Oct; 29(10):598-607. PubMed ID: 37481241
[TBL] [Abstract][Full Text] [Related]
11. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
12. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
[TBL] [Abstract][Full Text] [Related]
13. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
14. CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia.
Pacenta HL; Laetsch TW; John S
Paediatr Drugs; 2020 Feb; 22(1):1-11. PubMed ID: 31749131
[TBL] [Abstract][Full Text] [Related]
15. Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel.
Ravich JW; Huang S; Zhou Y; Brown P; Pui CH; Inaba H; Cheng C; Gottschalk S; Triplett BM; Bonifant CL; Talleur AC
Transplant Cell Ther; 2022 Feb; 28(2):73.e1-73.e9. PubMed ID: 34875402
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
17. [Safety and efficacy of CD19-targeted CAR-T cells in 14 patients with refractory/relapsed Philadelphia chromosome-positive acute B-precursor lymphoblastic leukemia].
He CX; Xue L; Qiang P; Xu H; Zhang XH; Liu X; Zhu WW; Cai XY; Liu HL; Sun ZM; Wang XB
Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):490-494. PubMed ID: 32654463
[No Abstract] [Full Text] [Related]
18. Bispecific CAR T-cells for B-cell Malignancies.
Furqan F; Shah NN
Expert Opin Biol Ther; 2022 Aug; 22(8):1005-1015. PubMed ID: 35653589
[TBL] [Abstract][Full Text] [Related]
19. Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia.
Shahid S; Ramaswamy K; Flynn J; Mauguen A; Perica K; Park JH; Forlenza CJ; Shukla NN; Steinherz PG; Margossian SP; Boelens JJ; Kernan NA; Curran KJ
Transplant Cell Ther; 2022 Feb; 28(2):72.e1-72.e8. PubMed ID: 34852305
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]